NVS | ||
---|---|---|
OUTLOOK RATING 1..100 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | |
SMR RATING 1..100 | 29 | |
PRICE GROWTH RATING 1..100 | 48 | |
P/E GROWTH RATING 1..100 | 79 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GINX | NVS | |
---|---|---|
RSI ODDS (%) | 3 days ago78% | 3 days ago56% |
Stochastic ODDS (%) | 3 days ago68% | 3 days ago44% |
Momentum ODDS (%) | 3 days ago80% | 3 days ago42% |
MACD ODDS (%) | 3 days ago87% | 3 days ago50% |
TrendWeek ODDS (%) | 3 days ago87% | 3 days ago49% |
TrendMonth ODDS (%) | 3 days ago82% | 3 days ago45% |
Advances ODDS (%) | 5 days ago87% | 3 days ago49% |
Declines ODDS (%) | 17 days ago60% | 12 days ago45% |
BollingerBands ODDS (%) | 3 days ago75% | 3 days ago43% |
Aroon ODDS (%) | 3 days ago90% | 3 days ago33% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MSVEX | 5.40 | 0.07 | +1.31% |
Morgan Stanley Vitality Portfolio A | |||
BRXUX | 16.30 | 0.03 | +0.18% |
MFS Blended Research Intl Eq R4 | |||
NCIGX | 32.82 | 0.05 | +0.15% |
Nuveen International Value C | |||
HQIRX | 21.63 | 0.02 | +0.09% |
Hartford Equity Income R3 | |||
MDGCX | 27.84 | -0.02 | -0.07% |
BlackRock Advantage Global Investor A |
A.I.dvisor tells us that GINX and KMB have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GINX and KMB's prices will move in lockstep.
Ticker / NAME | Correlation To GINX | 1D Price Change % | ||
---|---|---|---|---|
GINX | 100% | +0.47% | ||
KMB - GINX | 21% Poorly correlated | -0.34% | ||
GSK - GINX | 21% Poorly correlated | +1.44% | ||
KO - GINX | 20% Poorly correlated | +0.53% | ||
NVS - GINX | 20% Poorly correlated | +1.74% | ||
RELX - GINX | 19% Poorly correlated | +0.57% | ||
More |
A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.